Showing results (11-20 of 36) with videos related to
Sort By:
Pageof 4
Clinical Laboratory|July 13, 2012
The adoption of clinical pathways and the inclusion of likelihood ratios in the report: a controlled before and after studyMariacaterina Maconi, Roberto Baricchi, Maria Piera Ferrin, et al.Allergy, Asthma & Immunology Research|May 13, 2017
Real-life Efficacy of Omalizumab After 9 Years of Follow-upFrancesco Menzella, Carla Galeone, Debora Formisano, et al.Vaccines|November 17, 2020
Association between Exposure to Influenza Vaccination and COVID-19 Diagnosis and OutcomesPietro Ragni, Massimiliano Marino, Debora Formisano, et al.BMC Nursing|February 6, 2020
Linguistic-cultural validation of the oral health assessment tool (OHAT) for the Italian contextStefano Finotto, Giorgia Bertolini, Riccarda Camellini, et al.International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|November 5, 2025
Comparative evaluation of prophylactic strategies for postpartum hemorrhage in vaginal deliveryStefania Fieni, Giovanni Morganelli, Alissa Valenti, et al.Respiratory Care|May 23, 2012
Clinical audit on diagnostic accuracy and management of respiratory failure in COPDFrancesco Menzella, Nicola Facciolongo, Mirco Lusuardi, et al.Clinical Laboratory|December 23, 2008
Likelihood ratios reporting in a tertiary hospital emergency department; a pilot studyMariacaterina Maconi, Romolo M Dorizzi, Roberto Baricchi, et al.Head & Neck|August 26, 2010
CT cross-sectional imaging classification system for substernal goiter based on risk factors for an extracervical surgical approachGiuseppe Mercante, Enrico Gabrielli, Corrado Pedroni, et al.Journal of Cataract and Refractive Surgery|August 18, 2016
Bromfenac ophthalmic solution 0.09% as an adjunctive therapy to topical steroids after cataract surgery in pseudoexfoliation syndromeMarco Coassin, Alfonso Iovieno, Anna Soldani, et al.Therapeutic Advances in Respiratory Disease|February 11, 2012
Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-upFrancesco Menzella, Nicola Facciolongo, Roberto Piro, et al.Pageof 4